{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:34:18Z","timestamp":1771040058762,"version":"3.50.1"},"reference-count":94,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>While the incidence and survival associated with lymphoma have improved in recent years, outcome disparities related to sociodemographic factors such as age, sex, race, ethnicity, socioeconomic status (SES), and other social determinants of health (SDOH) remain prevalent in the modern era. Clinical trials are crucial for further improving outcomes, yet not all sociodemographic groups are equally represented in contemporary lymphoma trials. We conducted a systematic review of the literature evaluating the impact of SDOH on enrollment into clinical trials in the United States and identified 21 relevant studies. We confirmed that Black and Hispanic individuals are underrepresented in lymphoma clinical trials, due largely to the geographic distribution of clinical trial sites and exacerbated by globalization of cancer trials. Women may also be less appropriately represented than men, although this association is less robust and consistent. Adolescents and young adults with lymphoma who are older, treated at adult cancer centers, or managed by adult hematologists\/oncologists are all less likely to be part of trials. Older adults are also excluded from most lymphoma clinical trials. There is a dearth of data on how other SDOHs including education, employment, and household income contribute to differences in clinical trial enrollment. Further research is required to explore the intersection of demographics, SES, insurance status, and enrollment into lymphoma clinical trials.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf180","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T18:25:58Z","timestamp":1750789558000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of sociodemographic determinants on enrollment into contemporary lymphoma clinical trials: a systematic review"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4696-5110","authenticated-orcid":false,"given":"Jun Yang","family":"Jiang","sequence":"first","affiliation":[{"name":"Section of Hematology & Oncology, Department of Medicine, Baylor College of Medicine , Houston, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang","family":"Li","sequence":"additional","affiliation":[{"name":"Section of Hematology & Oncology, Department of Medicine, Baylor College of Medicine , Houston, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Romero","sequence":"additional","affiliation":[{"name":"Claremont McKenna College , Claremont, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9524-3990","authenticated-orcid":false,"given":"Christopher R","family":"Flowers","sequence":"additional","affiliation":[{"name":"Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9715-2577","authenticated-orcid":false,"given":"Chijioke","family":"Nze","sequence":"additional","affiliation":[{"name":"Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"2025063009422988700_CIT0001","author":"SEER*Explorer Application"},{"key":"2025063009422988700_CIT0002","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin."},{"key":"2025063009422988700_CIT0003","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med."},{"key":"2025063009422988700_CIT0004","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab-the world\u2019s first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol."},{"key":"2025063009422988700_CIT0005","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med."},{"key":"2025063009422988700_CIT0006","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"2025063009422988700_CIT0007","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med."},{"key":"2025063009422988700_CIT0008","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"2025063009422988700_CIT0009","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med."},{"key":"2025063009422988700_CIT0010","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet."},{"key":"2025063009422988700_CIT0011","doi-asserted-by":"publisher","first-page":"8","DOI":"10.21037\/aol.2017.11.01","article-title":"Disparities in lymphoma on the basis of race, gender, HIV status, and sexual orientation","volume":"1","author":"Becnel","year":"2017","journal-title":"Ann Lymphoma"},{"key":"2025063009422988700_CIT0012","doi-asserted-by":"publisher","first-page":"e0199745","DOI":"10.1371\/journal.pone.0199745","article-title":"Disparities by race, age, and sex in the improvement of survival for lymphoma: findings from a population-based study","volume":"13","author":"Mukhtar","year":"2018","journal-title":"PLoS One."},{"key":"2025063009422988700_CIT0013","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1093\/annonc\/mdr578","article-title":"Racial disparities in Hodgkin\u2019s lymphoma: a comprehensive population-based analysis","volume":"23","author":"Evens","year":"2012","journal-title":"Ann Oncol."},{"key":"2025063009422988700_CIT0014","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1002\/cncr.29518","article-title":"Disparities in survival by insurance status in patients with Hodgkin lymphoma","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer."},{"key":"2025063009422988700_CIT0015","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1634\/theoncologist.2014-0386","article-title":"Survival disparities by insurance type for patients aged 15-64 years with non-Hodgkin lymphoma","volume":"20","author":"Pulte","year":"2015","journal-title":"Oncologist."},{"key":"2025063009422988700_CIT0016","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3109\/10428194.2012.708751","article-title":"Examining racial differences in diffuse large B-cell lymphoma presentation and survival","volume":"54","author":"Flowers","year":"2013","journal-title":"Leuk Lymphoma."},{"key":"2025063009422988700_CIT0017","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canep.2014.12.001","article-title":"Racial differences in three major NHL subtypes: descriptive epidemiology","volume":"39","author":"Li","year":"2015","journal-title":"Cancer Epidemiol."},{"key":"2025063009422988700_CIT0018","author":"Social determinants of health","year":"."},{"key":"2025063009422988700_CIT0019","author":"CDC"},{"key":"2025063009422988700_CIT0020","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin."},{"key":"2025063009422988700_CIT0021","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3109\/10428194.2012.729831","article-title":"Incidence and survival patterns of cutaneous T-cell lymphomas in the United States","volume":"54","author":"Imam","year":"2013","journal-title":"Leuk Lymphoma."},{"key":"2025063009422988700_CIT0022","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.1002\/cncr.27513","article-title":"Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study","volume":"118","author":"Nabhan","year":"2012","journal-title":"Cancer."},{"key":"2025063009422988700_CIT0023","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1016\/j.clml.2019.03.006","article-title":"Racial and socioeconomic disparities in mantle cell lymphoma","volume":"19","author":"Shah","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2025063009422988700_CIT0024","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/ijc.34618","article-title":"Incidence of Burkitt lymphoma in the United States during 2000 to 2019","volume":"153","author":"Mburu","year":"2023","journal-title":"Int J Cancer."},{"key":"2025063009422988700_CIT0025","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/ijc.30576","article-title":"Survival predictors of Burkitt\u2019s lymphoma in children, adults and elderly in the United States during 2000-2013","volume":"140","author":"Mukhtar","year":"2017","journal-title":"Int J Cancer."},{"key":"2025063009422988700_CIT0026","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1200\/JCO.2015.63.5540","article-title":"Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States","volume":"34","author":"Adams","year":"2016","journal-title":"J Clin Oncol."},{"key":"2025063009422988700_CIT0027","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s10552-009-9382-3","article-title":"Disparities in survival after Hodgkin lymphoma: a population-based study","volume":"20","author":"Keegan","year":"2009","journal-title":"Cancer Causes Control."},{"key":"2025063009422988700_CIT0028","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/jnci\/djab028","article-title":"Cancer stage, treatment, and survival among transgender patients in the United States","volume":"113","author":"Jackson","year":"2021","journal-title":"J Natl Cancer Inst."},{"key":"2025063009422988700_CIT0029","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/aje\/kwg067","article-title":"Cancer in a population-based cohort of men and women in registered homosexual partnerships","volume":"157","author":"Frisch","year":"2003","journal-title":"Am J Epidemiol."},{"key":"2025063009422988700_CIT0030","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/cncr.28549","article-title":"Insurance status is related to diffuse large B-cell lymphoma survival","volume":"120","author":"Han","year":"2014","journal-title":"Cancer."},{"key":"2025063009422988700_CIT0031","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1182\/blood-2013-07-517110","article-title":"Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era","volume":"123","author":"Tao","year":"2014","journal-title":"Blood."},{"key":"2025063009422988700_CIT0032","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1634\/theoncologist.2015-0228","article-title":"Health insurance-related disparities in lymphoma survival are partly mediated by baseline clinical factors","volume":"20","author":"Olszewski","year":"2015","journal-title":"Oncologist."},{"key":"2025063009422988700_CIT0033","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1200\/JCO.2008.18.8052","article-title":"Improvements in survival after follicular lymphoma by race\/ethnicity and socioeconomic status: a population-based study","volume":"27","author":"Keegan","year":"2009","journal-title":"J Clin Oncol."},{"key":"2025063009422988700_CIT0034","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1080\/10428194.2021.1932873","article-title":"Comorbidities and socioeconomic status are predictors of survival in children and young adults with Burkitt lymphoma","volume":"62","author":"Alvarez","year":"2021","journal-title":"Leuk Lymphoma."},{"key":"2025063009422988700_CIT0035","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/1055-9965.EPI-15-0756","article-title":"Impact of treatment and insurance on socioeconomic disparities in survival after adolescent and young adult hodgkin lymphoma: a population-based study","volume":"25","author":"Keegan","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"2025063009422988700_CIT0036","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/bmt.2016.107","article-title":"Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma","volume":"51","author":"Hong","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"2025063009422988700_CIT0037","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1200\/JCO.2009.22.0038","article-title":"Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study","volume":"27","author":"Loberiza","year":"2009","journal-title":"J Clin Oncol."},{"key":"2025063009422988700_CIT0038","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA."},{"key":"2025063009422988700_CIT0039","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/jnci\/djy221","article-title":"Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation","volume":"111","author":"Unger","year":"2019","journal-title":"J Natl Cancer Inst."},{"key":"2025063009422988700_CIT0040","first-page":"5977","article-title":"Age and race distribution in patients in phase III oncology clinical trials","volume":"12","author":"Gopishetty","year":"2020","journal-title":"Am J Transl Res"},{"key":"2025063009422988700_CIT0041","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1371\/journal.pmed.0030019","article-title":"Are racial and ethnic minorities less willing to participate in health research","volume":"3","author":"Wendler","year":"2006","journal-title":"PLoS Med."},{"key":"2025063009422988700_CIT0042","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.23157","article-title":"Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review","volume":"112","author":"Ford","year":"2008","journal-title":"Cancer."},{"key":"2025063009422988700_CIT0043"},{"key":"2025063009422988700_CIT0044","doi-asserted-by":"publisher","first-page":"108602","DOI":"10.1016\/j.envint.2024.108602","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","volume":"186","author":"Higgins","year":"2024","journal-title":"Environ Int."},{"key":"2025063009422988700_CIT0045","doi-asserted-by":"publisher","first-page":"320","DOI":"10.7326\/M20-0410","article-title":"Participation of African American persons in clinical trials supporting U.S. food and drug administration approval of cancer drugs","volume":"173","author":"Al Hadidi","year":"2020","journal-title":"Ann Intern Med."},{"key":"2025063009422988700_CIT0046","doi-asserted-by":"publisher","first-page":"e228161","DOI":"10.1001\/jamanetworkopen.2022.8161","article-title":"Enrollment of black participants in pivotal clinical trials supporting US food and drug administration approval of chimeric antigen receptor-T Cell therapy for hematological malignant neoplasms","volume":"5","author":"Al Hadidi","year":"2022","journal-title":"JAMA Netw Open."},{"key":"2025063009422988700_CIT0047","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood.2023020052","article-title":"Representation of the population in need for pivotal clinical trials in lymphomas","volume":"142","author":"Casey","year":"2023","journal-title":"Blood."},{"key":"2025063009422988700_CIT0048","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.clml.2024.01.006","article-title":"Geographic and racial disparities in chimeric antigen receptor-T cells and bispecific antibodies trials access for diffuse large B-cell lymphoma","volume":"24","author":"Shahzad","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2025063009422988700_CIT0049","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/cncr.33463","article-title":"The impact of the globalization of cancer clinical trials on the enrollment of Black patients","volume":"127","author":"Tharakan","year":"2021","journal-title":"Cancer."},{"key":"2025063009422988700_CIT0050","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1182\/bloodadvances.2023011040","article-title":"Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHL","volume":"8","author":"Nze","year":"2024","journal-title":"Blood Adv."},{"key":"2025063009422988700_CIT0051","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMp1802313","article-title":"Making neighborhood-disadvantage metrics accessible - the neighborhood atlas","volume":"378","author":"Kind","year":"2018","journal-title":"N Engl J Med."},{"key":"2025063009422988700_CIT0052","doi-asserted-by":"publisher","first-page":"e181235","DOI":"10.1001\/jamanetworkopen.2018.1235","article-title":"Geographic distribution and survival outcomes for rural patients with cancer treated in clinical trials","volume":"1","author":"Unger","year":"2018","journal-title":"JAMA Netw Open."},{"key":"2025063009422988700_CIT0053","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/onco.13534","article-title":"Sex Representation in clinical trials associated with FDA cancer drug approvals differs between solid and hematologic malignancies","volume":"26","author":"Mendis","year":"2021","journal-title":"Oncologist."},{"key":"2025063009422988700_CIT0054","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1353\/hpu.0.0162","article-title":"Analysis of Maryland cancer patient participation in National Cancer Institute-supported cancer treatment clinical trials","volume":"20","author":"Baquet","year":"2009","journal-title":"J Health Care Poor Underserved."},{"key":"2025063009422988700_CIT0055","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1002\/cncr.33533","article-title":"Assessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: A systematic review-based cohort study","volume":"127","author":"Dymanus","year":"2021","journal-title":"Cancer."},{"key":"2025063009422988700_CIT0056","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1002\/cncr.29669","article-title":"Case-linked analysis of clinical trial enrollment among adolescents and young adults at a National Cancer Institute-designated comprehensive cancer center","volume":"121","author":"Collins","year":"2015","journal-title":"Cancer."},{"key":"2025063009422988700_CIT0057","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1097\/MPH.0b013e3181b91180","article-title":"A comparison of clinical trial enrollment between adolescent and young adult (AYA) oncology patients treated at affiliated adult and pediatric oncology centers","volume":"31","author":"Downs-Canner","year":"2009","journal-title":"J Pediatr Hematol Oncol."},{"key":"2025063009422988700_CIT0058","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1200\/JCO.2011.36.2954","article-title":"Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference","volume":"29","author":"Parsons","year":"2011","journal-title":"J Clin Oncol."},{"key":"2025063009422988700_CIT0059","doi-asserted-by":"publisher","first-page":"e27426","DOI":"10.1002\/pbc.27426","article-title":"Increased clinical trial enrollment among adolescent and young adult cancer patients between 2006 and 2012-2013 in the United States","volume":"66","author":"Parsons","year":"2019","journal-title":"Pediatr Blood Cancer."},{"key":"2025063009422988700_CIT0060","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/cncr.35078","article-title":"Alliance A151945: accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017","volume":"130","author":"Rosenberg","year":"2024","journal-title":"Cancer."},{"key":"2025063009422988700_CIT0061","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s00520-016-3558-7","article-title":"Clinical research participation among adolescent and young adults at an NCI-designated Comprehensive Cancer Center and affiliated pediatric hospital","volume":"25","author":"Sanford","year":"2017","journal-title":"Support Care Cancer."},{"key":"2025063009422988700_CIT0062","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1002\/cncr.31727","article-title":"A prospective comparison of cancer clinical trial availability and enrollment among adolescents\/young adults treated at an adult cancer hospital or affiliated children\u2019s hospital","volume":"124","author":"Thomas","year":"2018","journal-title":"Cancer."},{"key":"2025063009422988700_CIT0063","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1002\/cncr.33855","article-title":"Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years","volume":"127","author":"Unger","year":"2021","journal-title":"Cancer."},{"key":"2025063009422988700_CIT0064","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.ctrv.2013.01.007","article-title":"Barriers to inclusion of older adults in randomised controlled clinical trials on Non-Hodgkin\u2019s lymphoma: a systematic review","volume":"39","author":"Bellera","year":"2013","journal-title":"Cancer Treat Rev."},{"key":"2025063009422988700_CIT0065","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1182\/bloodadvances.2022007687","article-title":"Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER\/LEO cohort analysis","volume":"6","author":"Luan","year":"2022","journal-title":"Blood Adv."},{"key":"2025063009422988700_CIT0066","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/15284336.2018.1537349","article-title":"Participant characteristics and clinical trial decision-making factors in AIDS malignancy consortium treatment trials for HIV-infected persons with cancer (AMC #S006)","volume":"19","author":"Burkhalter","year":"2018","journal-title":"HIV Clin Trials."},{"key":"2025063009422988700_CIT0067","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1182\/blood.2023021222","article-title":"External validity of lymphoma clinical trials","volume":"142","author":"Calip","year":"2023","journal-title":"Blood."},{"key":"2025063009422988700_CIT0068","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1037\/hea0000242","article-title":"Understanding associations between race, socioeconomic status and health: patterns and prospects","volume":"35","author":"Williams","year":"2016","journal-title":"Health Psychol."},{"key":"2025063009422988700_CIT0069","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1245\/s10434-021-10868-4","article-title":"Access denied: inequities in clinical trial enrollment for pancreatic cancer","volume":"29","author":"Eskander","year":"2022","journal-title":"Ann Surg Oncol."},{"key":"2025063009422988700_CIT0070","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.1158\/1078-0432.CCR-10-1451","article-title":"The impact of insurance on access to cancer clinical trials at a comprehensive cancer center","volume":"16","author":"Klamerus","year":"2010","journal-title":"Clin Cancer Res."},{"key":"2025063009422988700_CIT0071","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1200\/JCO.2002.08.056","article-title":"How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials","volume":"20","author":"Sateren","year":"2002","journal-title":"J Clin Oncol."},{"key":"2025063009422988700_CIT0072","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamaoncol.2023.2800","article-title":"Medicaid expansion of the patient protection and affordable care act and participation of patients with medicaid in cancer clinical trials","volume":"9","author":"Unger","year":"2023","journal-title":"JAMA Oncol."},{"key":"2025063009422988700_CIT0073","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1182\/blood-2017-04-778225","article-title":"Racial and ethnic disparities in hematologic malignancies","volume":"130","author":"Kirtane","year":"2017","journal-title":"Blood."},{"key":"2025063009422988700_CIT0074","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.11213","article-title":"Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study","volume":"97","author":"Advani","year":"2003","journal-title":"Cancer."},{"key":"2025063009422988700_CIT0075","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s13187-011-0300-5","article-title":"The role of health literacy on African American and Hispanic\/Latino perspectives on cancer clinical trials","volume":"27","author":"Evans","year":"2012","journal-title":"J Cancer Educ."},{"key":"2025063009422988700_CIT0076","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/s41586-023-06382-0","article-title":"Consent document translation expense hinders inclusive clinical trial enrolment","volume":"620","author":"Velez","year":"2023","journal-title":"Nature."},{"key":"2025063009422988700_CIT0077","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1177\/1740774514522561","article-title":"Increasing Asian American participation in clinical trials by addressing community concerns","volume":"11","author":"Ma","year":"2014","journal-title":"Clin Trials."},{"key":"2025063009422988700_CIT0078","doi-asserted-by":"publisher","first-page":"10732748231187829","DOI":"10.1177\/10732748231187829","article-title":"Qualitative study of oncology clinicians\u2019 perceptions of barriers to offering clinical trials to underserved populations","volume":"30","author":"Perez","year":"2023","journal-title":"Cancer Control."},{"key":"2025063009422988700_CIT0079","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/onco.13767","article-title":"Patient-reported out-of-pocket costs and financial toxicity during early-phase oncology clinical trials","volume":"26","author":"Huey","year":"2021","journal-title":"Oncologist."},{"key":"2025063009422988700_CIT0080","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1182\/bloodadvances.2024012838","article-title":"Evaluating the impact of laboratory-based eligibility criteria by race\/ethnicity in first-line clinical trials of DLBCL","volume":"8","author":"Khurana","year":"2024","journal-title":"Blood Adv."},{"key":"2025063009422988700_CIT0081","author":"U.S. Food and Drug Administration"},{"key":"2025063009422988700_CIT0082","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJMp2209043","article-title":"New federal incentives for diversity in clinical trials","volume":"387","author":"Hwang","year":"2022","journal-title":"N Engl J Med."},{"key":"2025063009422988700_CIT0083","author":"U.S. Food and Drug Administration","journal-title":"Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies 2024"},{"key":"2025063009422988700_CIT0084","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1200\/OP.22.00429","article-title":"Experiences of a multiethnic cohort of patients enrolled in a financial reimbursement program for cancer clinical trials","volume":"19","author":"Medina","year":"2023","journal-title":"JCO Oncol Pract."},{"key":"2025063009422988700_CIT0085","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1634\/theoncologist.2019-0146","article-title":"Addressing the financial burden of cancer clinical trial participation: longitudinal effects of an equity intervention","volume":"24","author":"Nipp","year":"2019","journal-title":"Oncologist."},{"key":"2025063009422988700_CIT0086","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1200\/JCO.2005.22.236","article-title":"Increasing minority participation in cancer clinical trials: the minority-based community clinical oncology program experience","volume":"23","author":"McCaskill-Stevens","year":"2005","journal-title":"J Clin Oncol."},{"key":"2025063009422988700_CIT0087","doi-asserted-by":"publisher","first-page":"e7298","DOI":"10.1002\/cam4.7298","article-title":"Strategies for increasing accrual in cancer clinical trials: What is the evidence","volume":"13","author":"Michaels","year":"2024","journal-title":"Cancer Med."},{"key":"2025063009422988700_CIT0088","doi-asserted-by":"publisher","first-page":"pkab027","DOI":"10.1093\/jncics\/pkab027","article-title":"Barriers and facilitators to adolescent and young adult cancer trial enrollment: NCORP site perspectives","volume":"5","author":"Siembida","year":"2021","journal-title":"JNCI Cancer Spectr."},{"key":"2025063009422988700_CIT0089","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jncimonographs\/lgac019","article-title":"Enrolling older adults onto national cancer institute-funded clinical trials in community oncology clinics: barriers and solutions","volume":"2022","author":"Hopkins","year":"2022","journal-title":"J Natl Cancer Inst Monogr."},{"key":"2025063009422988700_CIT0090","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bjh.17436","article-title":"Evolution of eligibility criteria for diffuse large B-cell lymphoma randomised controlled trials over 30 years","volume":"193","author":"Loh","year":"2021","journal-title":"Br J Haematol."},{"key":"2025063009422988700_CIT0091","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1200\/JCO.20.01935","article-title":"Impact of organ function-based clinical trial eligibility criteria in patients with diffuse large B-cell lymphoma: who gets left behind","volume":"39","author":"Khurana","year":"2021","journal-title":"J Clin Oncol."},{"key":"2025063009422988700_CIT0092","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/bloodadvances.2021006504","article-title":"Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey","volume":"6","author":"Harkins","year":"2022","journal-title":"Blood Adv."},{"key":"2025063009422988700_CIT0093","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American society of clinical oncology-friends of cancer research HIV working group","volume":"35","author":"Uldrick","year":"2017","journal-title":"J Clin Oncol."},{"key":"2025063009422988700_CIT0094","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.1182\/blood-2024-208921","article-title":"Analyzing rates of exclusion among patients living with HIV in U.S.-based non-hodgkin lymphoma clinical trials from 2014-2024","volume":"144","author":"Olivieri","year":"2024","journal-title":"Blood."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf180\/63571178\/oyaf180.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf180\/63571178\/oyaf180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf180\/63571178\/oyaf180.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T13:42:40Z","timestamp":1751290960000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf180\/8173019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf180","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,6]]},"article-number":"oyaf180"}}